{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:48:11Z","timestamp":1762660091813,"version":"build-2065373602"},"reference-count":9,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Vaccines are actually the most effective strategy to control the COVID-19 spread and reduce mortality, but adverse reactions can occur. Skin involvement with novel messenger RNA coronavirus vaccines seems frequent but is not completely characterized. A real-world experience in the recent vaccination campaign among health care workers in Sardinia (Italy) is reported. In over a total of 1577 persons vaccinated, 9 cases of skin adverse reactions were observed (0.5%). All reactions have been reported to the Italian Pharmacovigilance Authority. Eight occurred in women (mean age 46 years), and five were physicians and four nurses. All patients had a significant allergology history but not for the known vaccine excipients. After dose one, no injection site reactions were observed, but widespread pruritus (n = 3), mild facial erythema (n = 1), and maculopapular rash (n = 3) occurred in the following 24\u201348 h in three patients. These three patients were excluded from the second dose. Of the remaining six patients, one developed mild anaphylaxis within the observation period at the vaccination hub and five delayed facial erythematous edema and maculopapular lesions, requiring antihistamines and short-course corticosteroid treatment. Spontaneous reporting is paramount to adjourning vaccination guidance and preventive measures in order to contribute to the development of a safe vaccine strategy. Dermatologist\u2019 expertise might provide better characterization, treatment, and screening of individuals at high risk of skin adverse reactions.<\/jats:p>","DOI":"10.3390\/diseases9030058","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T03:13:17Z","timestamp":1630465997000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Skin Adverse Reactions to Novel Messenger RNA Coronavirus Vaccination: A Case Series"],"prefix":"10.3390","volume":"9","author":[{"given":"Maria Francesca","family":"Peigottu","sequence":"first","affiliation":[{"name":"Dermatology Unit, San Francesco Hospital, 08100 Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-6791","authenticated-orcid":false,"given":"Caterina","family":"Ferreli","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department Medical Sciences and Public Health, Cagliari State University, 09124 Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giovanna","family":"Atzori","sequence":"additional","affiliation":[{"name":"Dermatology Unit, San Francesco Hospital, 08100 Nuoro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-1402","authenticated-orcid":false,"given":"Laura","family":"Atzori","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department Medical Sciences and Public Health, Cagliari State University, 09124 Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"ref_1","unstructured":"CDC (2020, December 21). COVID-19 Cases, Deaths, and Trends in the US|CDC COVID Data Tracker, Available online: https:\/\/covid.cdc.gov\/covid-data-tracker."},{"key":"ref_2","unstructured":"FDA (2020, December 21). Pfizer-BioNTech COVID-19 Vaccine, Available online: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontechcovid-19-vaccine."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","unstructured":"(2021, March 25). COVID-19 Vaccines for People with Allergies, Available online: https:\/\/www.cdc.gov."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wolfson, A.R., Robinson, L.B., Li, L., Cogan, A.S., Fu, X., Wickner, P., Samarakoon, U., Saff, R.R., Blumenthal, K.G., and Banerji, A. (2021). First Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. J. Allergy Clin. Immunol. Pract.","DOI":"10.1016\/j.jaip.2021.06.010"},{"key":"ref_6","unstructured":"Associazione Allergologi, Immunologi Italiani Territoriali e Ospedalieri, and Societ\u00e0 Italiana di Allergologia, Asma ed Immunologia Clinica (2021, January 15). Linee di Indirizzo per la Gestione da Parte Degli Allergologi dei Pazienti a Rischio di Reazioni Allergiche ai Vaccini per Covid-19. Available online: http:\/\/www.siaaic.org\/?p=5569."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.36849\/JDD.5899","article-title":"Coronavirus Vaccination Adverse Reactions and the Role of the Dermatologist","volume":"20","author":"Pulsipher","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jaip.2020.12.047","article-title":"mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach","volume":"9","author":"Banerji","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109420","DOI":"10.1016\/j.cbi.2021.109420","article-title":"Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis","volume":"338","author":"Hou","year":"2021","journal-title":"Chem.-Biol. Interact."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/9\/3\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:08Z","timestamp":1760165588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/9\/3\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["diseases9030058"],"URL":"https:\/\/doi.org\/10.3390\/diseases9030058","relation":{},"ISSN":["2079-9721"],"issn-type":[{"type":"electronic","value":"2079-9721"}],"subject":[],"published":{"date-parts":[[2021,8,27]]}}}